Latest Prilenia Therapeutics News & Updates

See the latest news and media coverage for Prilenia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Prilenia Therapeutics (Prilenia)

Clinical-stage biotech developing neurodegenerative disease treatments

prilenia.com

Headquarters: Boston, United States
Founded year: 2018
Company type: Private company
Number of employees: 10–70
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Prilenia Therapeutics (Prilenia)

In short: Prilenia advanced Phase 3 trials for Huntington's disease and ALS while expanding its leadership team and research collaborations.

Company announcements

September 8 Prilenia

Prilenia appoints Frederick Munschauer as chief medical officer

He brings extensive neurology experience from Biogen and recent clinical trial leadership roles to advance the company’s pivotal HD and ALS studies.

July 7 Prilenia

Prilenia and Ferrer initiate PRECISE-HD study for Huntington’s disease

The confirmatory trial will evaluate pridopidine in 400 participants across 75 sites, with a 52-week placebo-controlled stage and 104-week open-label extension.

May 26 Prilenia

Prilenia donates clinical trial datasets to CHDI Foundation

The data from placebo arms of PRIDE and PROOF studies will advance Huntington's disease research.

May 21 Prilenia

Prilenia Therapeutics' PREVAiLS Phase 3 study unboxed by ALS Society

The study evaluates pridopidine in ALS, with first Canadian patient enrolled and global recruitment across 13 countries.

Media coverage

July 7 Yahoo Finance

Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain, July 07, 2026--Prilenia Therapeutics B.V. and Ferreri today announced initiation of the confirmatory PRECISE-HD study (Pridopidine Phase...

April 28 Yahoo Finance

Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and...

April 3 Jammin 99.9

Breakthrough ALS study launches as drug aims to slow disease progression | Jammin 99.9 (WKXB FM)

The “PREVAiLS” study, which will review the investigational drug pridopidine as a potential ALS treatment, has already enrolled its first participant, according to a press...

March 30 Clinical Trials Arena

Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial

Prilenia Therapeutics and Ferrer have enrolled the first participant in the Phase III PREVAiLS trial assessing pridopidine in early ALS.

Never miss news about Prilenia

Track Prilenia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Prilenia competitors & trending companies

Browse news for competitors to Prilenia and other trending companies.